CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
We have now added a new section called the "Assay History List" to the "At A Gla...
A new Learning Center website will launch on Monday, March 30, 2020. While the link to the new Learn...